Gabriela Figueroa-González1, Claudia Vanessa Arellano-Gutiérrez2, Hernán Cortés3, Gerardo Leyva-Gómez4, Manuel González-Del Carmen5, Lilia Patricia Bustamante-Montes6, Miguel Rodríguez-Morales7, Israel López-Reyes8, Sofía Lizeth Alcaraz-Estrada9, Jorge Sandoval-Basilio10, Laura Itzel Quintas-Granados11, Octavio Daniel Reyes-Hernández12. 1. Pharmacogenetics Laboratory, UMIEZ, FES-Zaragoza, UNAM, Mexico City, Mexico. 2. Pharmacological Biochemistry Laboratory, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico. 3. Laboratory of Genomic Medicine, Department of Genomics, National Institute of Rehabilitation Luis Guillermo Ibarra Ibarra, Mexico City, Mexico. 4. Department of Pharmacy, Faculty of Chemistry, National Autonomous University of Mexico, Mexico City, Mexico. 5. Faculty of Medicine, University of Veracruz, Mendoza City, Veracruz, Mexico. 6. Dean of Health Sciences, Autonomous University of Guadalajara, Jalisco, Mexico. 7. Genomics Laboratory, National Cancer Institute, Mexico City, Mexico. 8. College of Sciences and Humanities, Autonomous University of Mexico City, Cuautepec Campus, Mexico City, Mexico. 9. Division of Genomic Medicine, National Medical Center '20 de Noviembre' ISSSTE, Mexico City, Mexico. 10. Molecular Biology Laboratory, Hipocrates University, Acapulco de Juarez, Guerrero, Mexico. 11. Bicentennial Mexican University, Tultitlán Higher Studies Unit, Mexico, Mexico. 12. Molecular Cancer Biology Laboratory, UMIEZ, FES-Zaragoza, UNAM, Mexico City, Mexico.
Abstract
CONTEXT: Four single-nucleotide polymorphisms (SNPs) in Mexican patients and their association with the development of breast cancer (BC). AIMS: This work is focused on determining the association of fibroblast growth factor receptor (rs12196489), TOX3 (rs3803662), human telomerase reverse transcriptase (h TERT, rs10069690), and FTO (rs17817449) polymorphisms and BC in a cohort of Mexican women. SETTINGS AND DESIGN: The study included 56 patients with a confirmed diagnosis of BC and 83 controls. Clinical characteristics were obtained from medical records. SUBJECTS AND METHODS: Genomic DNA from the samples was obtained from lymphocytes, and the genotyping of rs12196489, rs3803662, rs10069690, and rs17817449 polymorphisms was performed by real-time polymerase chain reaction using specific TaqMan probes. Statistical analysis was assessed to evaluate the distribution of genotype frequencies between cases and controls. STATISTICAL ANALYSIS: We used the STATA Statistical Package (version 10.1; STATA Corp., College Station, TX, USA). Student's t-test, χ2 test, or Fisher's exact test was used to evaluate the distribution of genotype frequencies. RESULTS: No statistical differences in allelic and genotypic frequencies were found between patients with BC and controls for SNPs: rs1219648, rs3803662, and rs17817449. Interestingly, according to the χ2 test, a significant difference was exhibited for rs10069690 (odds ratio = 0.095; 95% confidence interval = 0.038-0.214; P < 0.001). CONCLUSIONS: The h TERT (rs10069690) polymorphism might be associated with BC in Mexican women. Nevertheless, additional studies in a larger cohort are required to confirm this association and to possibly use this polymorphism as a potential biomarker in the early diagnosis of BC.
CONTEXT: Four single-nucleotide polymorphisms (SNPs) in Mexican patients and their association with the development of breast cancer (BC). AIMS: This work is focused on determining the association of fibroblast growth factor receptor (rs12196489), TOX3 (rs3803662), human telomerase reverse transcriptase (h TERT, rs10069690), and FTO (rs17817449) polymorphisms and BC in a cohort of Mexican women. SETTINGS AND DESIGN: The study included 56 patients with a confirmed diagnosis of BC and 83 controls. Clinical characteristics were obtained from medical records. SUBJECTS AND METHODS: Genomic DNA from the samples was obtained from lymphocytes, and the genotyping of rs12196489, rs3803662, rs10069690, and rs17817449 polymorphisms was performed by real-time polymerase chain reaction using specific TaqMan probes. Statistical analysis was assessed to evaluate the distribution of genotype frequencies between cases and controls. STATISTICAL ANALYSIS: We used the STATA Statistical Package (version 10.1; STATA Corp., College Station, TX, USA). Student's t-test, χ2 test, or Fisher's exact test was used to evaluate the distribution of genotype frequencies. RESULTS: No statistical differences in allelic and genotypic frequencies were found between patients with BC and controls for SNPs: rs1219648, rs3803662, and rs17817449. Interestingly, according to the χ2 test, a significant difference was exhibited for rs10069690 (odds ratio = 0.095; 95% confidence interval = 0.038-0.214; P < 0.001). CONCLUSIONS: The h TERT (rs10069690) polymorphism might be associated with BC in Mexican women. Nevertheless, additional studies in a larger cohort are required to confirm this association and to possibly use this polymorphism as a potential biomarker in the early diagnosis of BC.
Entities:
Keywords:
Breast cancer; Mexican population; cancer risk factors; genetic polymorphisms; human telomerase reverse transcriptase